Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats

Anti-Cancer Drugs

Volumn 8, Issue 9, 1997, Pages 835-844

  Stehle, Gerd ^a,b   Wunder, Andreas ^a   Sinn, Hannsjörg ^a   Schrenk, Hans Herrmann ^a   Schütt, Sandra ^a   Frei, Eva ^b   Hartung, Gernot ^b   Maier Borst, Wolfgang ^a   Heene, Dieter L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

256 carcinosarcoma Walker; Drug carriers; Methotrexate; Pharmacokinetics; Pharmacology; Residualizing labels; Scintigraphy.

Indexed keywords

DRUG CARRIER; METHOTREXATE; METHOTREXATE ALBUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTINUOUS INFUSION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TISSUE LEVEL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; WALKER CARCINOMA;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; CARCINOMA 256, WALKER; FEMALE; INDICATORS AND REAGENTS; INDIUM RADIOISOTOPES; LIVER; METHOTREXATE; PENTETIC ACID; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; TISSUE DISTRIBUTION;

EID: 0030659779     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199710000-00004     Document Type: Article

References (31)

1. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814-9s.
2. Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev 1984; 36: 277-336.
3. Juliano RL. Targeted drug delivery. Berlin: Springer Verlag 1991.
4. Takakura Y, Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular pro-drugs. Crit Rev Oncol Hematol 1995; 18: 207-31.
5. Singh M, Ferdous AJ, Branham M, Betageri GV. Trends in drug targeting for cancer treatment. Drug Delivery 1996; 3: 289-304.
6. Stehle G, Sinn H, Wunder A, Schrenk HH, Heene DL, Maier-Borst W. The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats. Anti-Cancer Drugs 1997; 8: 677-85.
7. Peters T. All about albumin: biochemistry, genetics and medical applications. San Diego: Academic Press 1996: 1-432.
8. Sinn H, Schrenk HH, Friedrich EA, Schilling U, Maier Borst W. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int J Radiat Appl Instrum B 1990; 17: 819-27.
9. Schilling U, Friedrich EA, Sinn H, Schrenk HH, Clorius JH. Maier Borst W. Design of compounds having enhanced tumour uptake, using serum albumin as a carrier - Part II. In vivo studies. Int J Radiat Appl Instrum B 1992; 19: 685-95.
10. Wunder A, Stehle G, Sinn H, et al. Enhanced albumin uptake by rat tumors. Int J Oncol 1997; 11: 497-507.
11. Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself - implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997; 26: 77-100.
12. Lee HB, Blaufox MD. Blood volume in the rat. J Nucl Med 1985; 26: 72-6.
13. Wunder A, Stehle G, Sinn H, et al. Antitumor activity of MTX-HSA conjugates in rats. Eur J Cancer 1997; 33(suppl 8): S178-9.
14. Heinzel G, Woloszczack R, Thomann P. TOPFIT 2.0: pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer 1993.
15. Thorpe SR, Baynes JW, Chroneos ZC. The design and application of residualizing labels for the studies of protein catabolism. FASEB J 1993; 7: 399-405.
16. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 1993; 34: 1728-38.
17. Rogers BE, Franano FN, Duncan JR, et al. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res 1995; 55: 5714-20s.
18. Arano Y, Mukai T, Akizawa H, et al. Radiolabeled metabolites of proteins play a critical role in radioactivity elimination from the liver. Nucl Med Biol 1995; 22: 555-64.
19. Behr TM, Becker WS, Sharkey RM, et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996; 37: 829-33.
20. Behr TM, Goldenberg DM. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides? J Nucl Med 1996; 37: 834-6.
21. Hartung G, Stehle G, Sinn H, et al. Phase 1 trial of a methotrexate-albumin conjugate (MTX-HSA) in cancer patients. Eur J Cancer 1997; 33(suppl 8): S249-50.
22. Allen TM. Toxicity of drug carriers to the mononuclear phagocyte system. Adv Drug Deliv Rev 1988; 2: 55-67.
23. Evans WE, Crom WR, Yalowich JC. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, Harrison H, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Spokane, WA: Applied Therapeutics 1986; 1009-56.
24. Bertino JR. Ode to methotrexate. J Clin Oncol 1993; 11: 5-14.
25. Samuels LL, Feinberg A, Moccio DM, Sirotnak FM, Rosen G. Detection by high-performance liquid chromatography of methotrexate and its metabolites in tumor tissue from osteosarcoma patients treated with high-close methotrexate/leucovorin rescue. Biochem Pharmacol 1984; 33: 2711-4.
26. Winick NJ, Kamen BA, Streckfuss A, et al. Methotrexate (MTX) concentration in tumors following low-dose MTX. Cancer Chemother Pharmacol 1987; 20: 78-80.
27. Meyer WH, Loftin SK, Houghton JA, Houghton PJ. Accumulation, intracellular metabolism, and antitumor activity of high- and low-dose methotrexate in human osteosorcoma xenografts. Cancer Commun 1990; 2: 219-29.
28. Kipp JB, Kal MB, van Gennip AH, van Berkel AH. Treatment of the rat R-1 rhabdomyosarcoma with methotrexate and radiation; effects of timing on cell survival and tumour growth delay. J Cancer Res Clin Oncol 1993; 119: 215-20.
29. Kipp JBA, Leyva A, van Gennip AH, Kal HB. Pharmacokinetics and biological responses after treatment of the rat R-1 rhabdomyosarcoma with methotrexate. Int J Cancer 1993; 54: 945-51.
30. Kipp JBA, van Gennip AH, Leyva A, Kal HB. Pharmacokinetics of methotexate and concentrations attained in tumor tissue after treatment of rat R1-rhabdomyosarcoma. Reg Cancer Treat 1993; 1: 49-56.
31. Hartung G, Heeger S, Schrenk HH. Stehle G, Sinn H, Queisser W. Drug-monitoring of methotrexate covalently bound to human serum albumin (MTX-HSA) with homogeneous enzyme multiplied immunoassay technique (EMIT) in a phase 1 trial. Ann Hematol 1996; 73 (suppl II): A50.